ERIS Lifescience

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE406M01024
NSEID: ERIS
BSEID: 540596
View on NSE | View on BSE

INR

1,346.70

14.9 (1.12%)

BSENSE

May 14

BSE+NSE Vol: 13.3 k

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,346.70",
    "chg": 14.9,
    "chgp": "1.12%",
    "dir": 1,
    "prev_price": "1,331.80",
    "mcapval": "18,660.86 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "May 14",
    "curr_time": "",
    "bse_nse_vol": "13.3 k",
    "exc_status": "Active",
    "traded_date": "May 14, 2026",
    "traded_date_str": "2026 05 14",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3990343",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_3990343.png",
        "date": "2026-05-14 08:00:48",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of early February 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player differently against its peers and historical benchmarks."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3982747",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_3982747.png",
        "date": "2026-05-09 10:10:36",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-growing-price-pressure-amid-sector-comparisons-3974669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_3974669.png",
        "date": "2026-05-05 08:01:25",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3967388",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_valuationdot_3967388.png",
        "date": "2026-04-29 08:00:46",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3966332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_mojoScore_3966332.png",
        "date": "2026-04-28 10:10:55",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3960144",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_technicaldot_3960144.png",
        "date": "2026-04-24 08:03:17",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges."
      },
      {
        "title": "ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-faces-bearish-momentum-amid-technical-downgrade-3958463",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_technicaldot_3958463.png",
        "date": "2026-04-23 08:03:19",
        "description": "ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 09 Feb 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price declining 2.45% on 23 Apr 2026 to ₹1,344.50, reflecting a broader trend of weakening momentum."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3950643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_mojoScore_3950643.png",
        "date": "2026-04-17 10:10:58",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "ERIS Lifesciences Gains 3.18%: Valuation Concerns and Technical Shifts Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-gains-318-valuation-concerns-and-technical-shifts-shape-the-week-3942679",
        "imagepath": "",
        "date": "2026-04-11 13:02:27",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>6 Apr:</strong> Week opens at Rs.1,328.05</p>\n                    <p><strong>7 Apr:</strong> Stock dips 0.81% despite Sensex rise</p>\n                    <p><strong>8 Apr:</strong> Strong rebound with 2.47% gain on heavy volume</p>\n                    <p><strong>9 Apr:</strong> Valuation downgrade announced; stock rises 0.96%</p>\n                    <p><strong>10 Apr:</strong> Technical momentum shifts mildly bullish; closes at Rs.1,370.30 (+0.55%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,328.05</div></div>\n                    <div class=\"stat-i..."
      }
    ],
    "total": 317,
    "sid": "1002771",
    "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Credit Rating Of Eris Threpeutics Limited",
      "datetime": "12-May-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
      "datetime": "11-May-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "08-May-2026",
      "details": "as attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>735%</strong> dividend, ex-date: 13 Feb 25",
          "dt": "2025-02-13",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-05-14 08:00:48

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of early February 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player differently against its peers and historical benchmarks.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-05-09 10:10:36

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons

2026-05-05 08:01:25

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-04-29 08:00:46

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-04-28 10:10:55

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-24 08:03:17

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges.

Read full news article

ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-04-23 08:03:19

ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 09 Feb 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price declining 2.45% on 23 Apr 2026 to ₹1,344.50, reflecting a broader trend of weakening momentum.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-04-17 10:10:58

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.